Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT04484012 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions

DRUG: Acalabrutinib
BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Sponsor

City of Hope Medical Center

Collaborators

[object Object]